Dementia with Lewy bodies

Ian McKeith, Jacobo Mintzer, Dag Aarsland, David Burn, Helen Chiu, Jiska Cohen-Mansfield, Dennis W Dickson, Bruno Dubois, John E. Duda, Howard Feldman, Serge Gauthier, Glenda Halliday, Brian Lawlor, Carol Lippa, Oscar L. Lopez, João Carlos MacHado, John O'Brien, Jeremy Playfer, Wayne Reid

Research output: Contribution to journalArticle

568 Citations (Scopus)

Abstract

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalLancet Neurology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Lewy Body Disease
Dementia
Synucleins
Neurobehavioral Manifestations
Cholinesterase Inhibitors
Neurodegenerative Diseases
Antipsychotic Agents
Parkinson Disease
Pathology
Morbidity
Mortality
Proteins

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., ... Reid, W. (2004). Dementia with Lewy bodies. Lancet Neurology, 3(1), 19-28. https://doi.org/10.1016/S1474-4422(03)00619-7

Dementia with Lewy bodies. / McKeith, Ian; Mintzer, Jacobo; Aarsland, Dag; Burn, David; Chiu, Helen; Cohen-Mansfield, Jiska; Dickson, Dennis W; Dubois, Bruno; Duda, John E.; Feldman, Howard; Gauthier, Serge; Halliday, Glenda; Lawlor, Brian; Lippa, Carol; Lopez, Oscar L.; Carlos MacHado, João; O'Brien, John; Playfer, Jeremy; Reid, Wayne.

In: Lancet Neurology, Vol. 3, No. 1, 01.01.2004, p. 19-28.

Research output: Contribution to journalArticle

McKeith, I, Mintzer, J, Aarsland, D, Burn, D, Chiu, H, Cohen-Mansfield, J, Dickson, DW, Dubois, B, Duda, JE, Feldman, H, Gauthier, S, Halliday, G, Lawlor, B, Lippa, C, Lopez, OL, Carlos MacHado, J, O'Brien, J, Playfer, J & Reid, W 2004, 'Dementia with Lewy bodies', Lancet Neurology, vol. 3, no. 1, pp. 19-28. https://doi.org/10.1016/S1474-4422(03)00619-7
McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al. Dementia with Lewy bodies. Lancet Neurology. 2004 Jan 1;3(1):19-28. https://doi.org/10.1016/S1474-4422(03)00619-7
McKeith, Ian ; Mintzer, Jacobo ; Aarsland, Dag ; Burn, David ; Chiu, Helen ; Cohen-Mansfield, Jiska ; Dickson, Dennis W ; Dubois, Bruno ; Duda, John E. ; Feldman, Howard ; Gauthier, Serge ; Halliday, Glenda ; Lawlor, Brian ; Lippa, Carol ; Lopez, Oscar L. ; Carlos MacHado, João ; O'Brien, John ; Playfer, Jeremy ; Reid, Wayne. / Dementia with Lewy bodies. In: Lancet Neurology. 2004 ; Vol. 3, No. 1. pp. 19-28.
@article{7eacd52c336d4e208ce98e9c4c182774,
title = "Dementia with Lewy bodies",
abstract = "Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.",
author = "Ian McKeith and Jacobo Mintzer and Dag Aarsland and David Burn and Helen Chiu and Jiska Cohen-Mansfield and Dickson, {Dennis W} and Bruno Dubois and Duda, {John E.} and Howard Feldman and Serge Gauthier and Glenda Halliday and Brian Lawlor and Carol Lippa and Lopez, {Oscar L.} and {Carlos MacHado}, Jo{\~a}o and John O'Brien and Jeremy Playfer and Wayne Reid",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/S1474-4422(03)00619-7",
language = "English (US)",
volume = "3",
pages = "19--28",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Dementia with Lewy bodies

AU - McKeith, Ian

AU - Mintzer, Jacobo

AU - Aarsland, Dag

AU - Burn, David

AU - Chiu, Helen

AU - Cohen-Mansfield, Jiska

AU - Dickson, Dennis W

AU - Dubois, Bruno

AU - Duda, John E.

AU - Feldman, Howard

AU - Gauthier, Serge

AU - Halliday, Glenda

AU - Lawlor, Brian

AU - Lippa, Carol

AU - Lopez, Oscar L.

AU - Carlos MacHado, João

AU - O'Brien, John

AU - Playfer, Jeremy

AU - Reid, Wayne

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

AB - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

UR - http://www.scopus.com/inward/record.url?scp=9144224226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144224226&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(03)00619-7

DO - 10.1016/S1474-4422(03)00619-7

M3 - Article

C2 - 14693108

AN - SCOPUS:9144224226

VL - 3

SP - 19

EP - 28

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -